# Janux Therapeutics, Inc. (JANX) stock: price and valuation

URL: https://funkfolio.com/stock/JANX

> Janux Therapeutics, Inc. (JANX) trades at $10.71, is worth $655.27M and scores 42/100. Valuation, financials and signals.

---

## Janux Therapeutics, Inc. (JANX)

Janux Therapeutics, Inc. (JANX) is a healthcare company (biotechnology) based in the United States. The share price is $10.71, down 1.92% on the day, which values the company at $655.27M. Price as of 17 Nov 2026, 23:46 UTC, from Yahoo Finance.

### Key facts

- **Share price:** $10.71 −1.92% today
- **Market value:** $655.27M
- **Funk Score:** 42/100
- **Against its own history:** Well below its usual price usual price $17.88
- **200-week average:** $24.61 56% below
- **Sector:** Healthcare

Figures as of 17 Nov 2026, 23:46 UTC. Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.

### Janux Therapeutics, Inc. in more detail

JANX trades at -4.2× next year's expected earnings, 28.1× sales. Measured against its own history, the price is 40% below what its usual multiples would imply ($17.88) — well below its usual price. It sits 56% below its 200-week average of $24.61.

Its Funk Score is 42 out of 100 (financial strength 7.5, profitability 0.0, growth 4.3, value 5.0, each out of 10).

In its favour: Altman Z in the safe zone; More cash than debt. Worth checking: Weak Piotroski score; Share count keeps rising.

1 of the superinvestors tracked here hold JANX, including Peter Kolchinsky (1.5% of the portfolio).

### Superinvestors holding JANX

1 of the investors tracked here report a position in their latest 13F filing.

- [Peter Kolchinsky RA Capital Management](https://funkfolio.com/gurus/peter-kolchinsky) 1.49% of portfolio · $171.9M · Q2 2026

### Janux Therapeutics, Inc. (JANX): questions and answers

**What is Janux Therapeutics, Inc.'s market cap?**

Janux Therapeutics, Inc. is valued at $655.27M at a share price of $10.71.

**Is JANX overvalued or undervalued?**

Against its own history, JANX is well below its usual price: the price is 40% below the $17.88 implied by the median multiples it has traded at (price / sales, price / book). That compares the stock with its past; it does not say whether the business now deserves a higher or lower multiple.

**Is JANX above its 200-week moving average?**

No. JANX is 56.5% below its 200-week average of $24.61. Long-term investors watch that line because strong companies rarely trade below it for long.

**How fast is Janux Therapeutics, Inc. growing?**

Over the last three fiscal years Janux Therapeutics, Inc.'s revenue grew 5.1% a year.

**Does JANX pay a dividend?**

Janux Therapeutics, Inc. does not currently pay a regular dividend.

**Which famous investors own JANX?**

In their latest quarterly filings, Peter Kolchinsky (1.5% of the portfolio) hold JANX. These filings are published up to 45 days after each quarter ends, so positions may have changed since.

### Learn to read these numbers

[All stocks guides →](https://funkfolio.com/learn/stocks)

- [Altman Z-score: formula, zones and where it fails](https://funkfolio.com/learn/stocks/altman-z-score)

  The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- [Analyst price targets and ratings: what they mean](https://funkfolio.com/learn/stocks/analyst-price-targets)

  An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- [Free cash flow and FCF yield explained](https://funkfolio.com/learn/stocks/free-cash-flow)

  Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.

### Cite this page

Funkfolio, “Janux Therapeutics, Inc. (JANX) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/JANX

Underlying data: Yahoo Finance; company filings with the SEC.
